Dashboard
Manage Tickers

CLMT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-calumet-maintains-33-price-target
HC Wainwright & Co. Reiterates Buy on Calu...
11/10/2025 11:13:07

HC Wainwright & Co. analyst Amit Dayal reiterates Calumet (NASDAQ:CLMT) with a Buy and maintains $33 price target.

calumet-specialty-prods-q3-eps-361-may-not-compare-to-038-estimate-sales-1078b-beat-1052b-estimate
Calumet Specialty Prods Q3 EPS $3.61 May N...
11/07/2025 12:06:09

earnings-scheduled-for-november-7-2025
Earnings Scheduled For November 7, 2025
11/07/2025 11:11:23

preview-calumet-specialty-prodss-earnings
Preview: Calumet Specialty Prods's Earnings
11/06/2025 16:03:14

goldman-sachs-maintains-buy-on-calumet-raises-price-target-to-20
Goldman Sachs Maintains Buy on Calumet, Ra...
10/22/2025 16:45:48

Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $15 to $20.

calumet-wins-epa-approval-for-small-refinery-exemptions-slashes-rin-liability-by-over-75
Calumet Wins EPA Approval For Small Refine...
08/26/2025 11:43:56

Calumet, Inc. (NASDAQ:CLMT) ("Calumet, ""we," "our" or "us") provided an update regarding the r...

ubs-maintains-neutral-on-calumet-raises-price-target-to-1325
UBS Maintains Neutral on Calumet, Raises P...
08/12/2025 13:49:35

UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $12 to $13.25.

calumet-specialty-prods-q2-eps-170-misses-031-estimate-sales-103b-beat-91673m-estimate
Calumet Specialty Prods Q2 EPS $(1.70) Mis...
08/08/2025 11:01:47

Core News & Articles
Earnings Scheduled For August 8, 2025
08/08/2025 08:32:13

insights-into-calumet-specialty-prodss-upcoming-earnings
Insights into Calumet Specialty Prods's Up...
08/07/2025 15:06:30

calumet-extends-shreveport-terminal-financing-arrangement-with-stonebriar-unlocks-80m-proceeds-via-120m-asset-revaluation
Calumet Extends Shreveport Terminal Financ...
07/28/2025 11:54:13

Calumet, Inc. (NASDAQ:CLMT) ("Calumet" or the "Company") announced today that it has extended its Shreveport te...

wells-fargo-maintains-overweight-on-calumet-lowers-price-target-to-21
Wells Fargo Maintains Overweight on Calume...
05/14/2025 14:25:26

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $23 to $21.

calumet-renewables-expansion-is-unlocking-value-analyst
Calumet Renewables Expansion Is Unlocking ...
05/13/2025 19:10:10

Calumet shares rise after analyst highlights MaxSAF-driven EBITDA growth and debt reduction potential.

b-of-a-securities-initiates-coverage-on-calumet-with-buy-rating-announces-price-target-of-15
B of A Securities Initiates Coverage On Ca...
05/13/2025 13:08:07

B of A Securities analyst Conor Fitzpatrick initiates coverage on Calumet (NASDAQ:CLMT) with a Buy rating and announces Pric...

calumet-specialty-prods-q1-eps-187-misses-057-estimate-sales-99390m-beat-89144m-estimate
Calumet Specialty Prods Q1 EPS $(1.87) Mis...
05/09/2025 11:03:24

Calumet Specialty Prods (NASDAQ:CLMT) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimat...

Core News & Articles
Earnings Scheduled For May 9, 2025
05/09/2025 08:32:15

what-to-expect-from-calumet-specialty-prodss-earnings
What to Expect from Calumet Specialty Prod...
05/08/2025 17:01:03

goldman-sachs-maintains-buy-on-calumet-lowers-price-target-to-14
Goldman Sachs Maintains Buy on Calumet, Lo...
04/30/2025 16:56:47

Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and lowers the price target from $16 to $14.

wells-fargo-maintains-overweight-on-calumet-lowers-price-target-to-23
Wells Fargo Maintains Overweight on Calume...
04/09/2025 18:41:32

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $28 to $23.

calumet-reveals-intention-to-nominate-julio-quintana-and-karen-narwold-to-board-wasserstein-debt-opportunities-expresses-support
Calumet Reveals Intention To Nominate Juli...
03/17/2025 22:01:06

Jim Carter and Dan Sheets have informed the Board of their decision not to seek re-election and to retire at the end of their t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION